DO 24
Alternative Names: DO-24Latest Information Update: 28 Dec 2024
At a glance
- Originator Metis Precision Medicine
- Class Monoclonal antibodies; Vascular disorder therapies
- Mechanism of Action Proto-oncogene protein c-met stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Chemotherapy-induced damage; Stroke
Most Recent Events
- 28 Dec 2024 No recent reports of development identified for research development in Chemotherapy-induced-damage in Italy (Parenteral)
- 28 Dec 2024 No recent reports of development identified for research development in Stroke in Italy (Parenteral)
- 10 Nov 2020 Early research in Chemotherapy-induced damage (chemotherapy-induced oxidative stress in cardiac and skeletal muscles) in Italy (Parenteral) before November 2020 (Metis Precision Medicine pipeline, November 2020)